Regencell Bioscience Holdings Ltd (RGC) Stock Analysis

Regencell Bioscience Holdings Ltd (RGC) is a publicly traded company in the HEALTHCARE sector. It trades at $23.15, carries a market capitalization of $11.96B. This page summarizes the public market data, fundamentals, and frequently asked questions for RGC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Regencell Bioscience Holdings Ltd currently has a Bearish sentiment score of -0.44.

About Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd is a biotechnology company focused on developing innovative therapeutic solutions that leverage advanced bioscience methodologies. Headquartered in Hong Kong, the company aims to address significant healthcare challenges through its proprietary research and development efforts. Regencell is positioned to capitalize on the growing demand for effective treatment alternatives in various medical sectors, offering institutional investors an opportunity to engage i...

GNG Research Analysis

GNG Research scores Regencell Bioscience Holdings Ltd (RGC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RGC.

Frequently Asked Questions

Does RGC pay dividends?

Regencell Bioscience Holdings Ltd (RGC) does not currently pay a regular dividend.

What is RGC's market cap?

Regencell Bioscience Holdings Ltd (RGC) has a market capitalization of $11.96B with a current stock price of $23.15.